243 related articles for article (PubMed ID: 9563903)
61. Frequent deregulation of p16 and the p16/G1 cell cycle-regulatory pathway in neuroblastoma.
Diccianni MB; Omura-Minamisawa M; Batova A; Le T; Bridgeman L; Yu AL
Int J Cancer; 1999 Jan; 80(1):145-54. PubMed ID: 9935245
[TBL] [Abstract][Full Text] [Related]
62. Expression of p16INK4a suppresses the unbounded and anchorage-independent growth of a glioblastoma cell line that lacks p16INK4a.
Higashi H; Suzuki-Takahashi I; Yoshida E; Nishimura S; Kitagawa M
Biochem Biophys Res Commun; 1997 Feb; 231(3):743-50. PubMed ID: 9070885
[TBL] [Abstract][Full Text] [Related]
63. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1.
Maelandsmo GM; Berner JM; Flørenes VA; Forus A; Hovig E; Fodstad O; Myklebost O
Br J Cancer; 1995 Aug; 72(2):393-8. PubMed ID: 7640224
[TBL] [Abstract][Full Text] [Related]
64. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6.
Tang LH; Contractor T; Clausen R; Klimstra DS; Du YC; Allen PJ; Brennan MF; Levine AJ; Harris CR
Clin Cancer Res; 2012 Sep; 18(17):4612-20. PubMed ID: 22761470
[TBL] [Abstract][Full Text] [Related]
65. Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia.
Chilosi M; Doglioni C; Yan Z; Lestani M; Menestrina F; Sorio C; Benedetti A; Vinante F; Pizzolo G; Inghirami G
Am J Pathol; 1998 Jan; 152(1):209-17. PubMed ID: 9422538
[TBL] [Abstract][Full Text] [Related]
66. [Expression of CDK4 protein in oral carcinogenesis].
Chen Q; Luo G; Li B; He Z; Chen L; Cao X; Nie M
Hua Xi Kou Qiang Yi Xue Za Zhi; 1999 Feb; 17(1):8-10. PubMed ID: 12539309
[TBL] [Abstract][Full Text] [Related]
67. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
[TBL] [Abstract][Full Text] [Related]
68. Alteration of pRb/p16/cdk4 regulation in human osteosarcoma.
Benassi MS; Molendini L; Gamberi G; Ragazzini P; Sollazzo MR; Merli M; Asp J; Magagnoli G; Balladelli A; Bertoni F; Picci P
Int J Cancer; 1999 Oct; 84(5):489-93. PubMed ID: 10502725
[TBL] [Abstract][Full Text] [Related]
69. [The expressions of p16, CDK4 and PCNA proteins in trophoblastic tumors].
Fu C; Zhang Q; Lu F; Zhang Z; Hu Y; Lin L
Hunan Yi Ke Da Xue Xue Bao; 1998; 23(1):17-20. PubMed ID: 10681785
[TBL] [Abstract][Full Text] [Related]
70. [The expression of Rb, p16 and cyclin D1 in 41 esophageal cancers].
Zheng J; Zhou C; Xiao F
Zhonghua Bing Li Xue Za Zhi; 1996 Dec; 25(6):336-9. PubMed ID: 9388858
[TBL] [Abstract][Full Text] [Related]
71. Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors.
Sotillo R; Dubus P; Martín J; de la Cueva E; Ortega S; Malumbres M; Barbacid M
EMBO J; 2001 Dec; 20(23):6637-47. PubMed ID: 11726500
[TBL] [Abstract][Full Text] [Related]
72. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours.
Dei Tos AP; Doglioni C; Piccinin S; Sciot R; Furlanetto A; Boiocchi M; Dal Cin P; Maestro R; Fletcher CD; Tallini G
J Pathol; 2000 Apr; 190(5):531-6. PubMed ID: 10727978
[TBL] [Abstract][Full Text] [Related]
73. Aberrations of p16Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines.
Aagaard L; Lukas J; Bartkova J; Kjerulff AA; Strauss M; Bartek J
Int J Cancer; 1995 Mar; 61(1):115-20. PubMed ID: 7705923
[TBL] [Abstract][Full Text] [Related]
74. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas.
Burns KL; Ueki K; Jhung SL; Koh J; Louis DN
J Neuropathol Exp Neurol; 1998 Feb; 57(2):122-30. PubMed ID: 9600204
[TBL] [Abstract][Full Text] [Related]
75. Characterization of a highly conserved gene (OS4) amplified with CDK4 in human sarcomas.
Su YA; Lee MM; Hutter CM; Meltzer PS
Oncogene; 1997 Sep; 15(11):1289-94. PubMed ID: 9315096
[TBL] [Abstract][Full Text] [Related]
76. Analysis of cyclin-dependent kinase inhibitor expression and methylation patterns in human prostate cancers.
Nguyen TT; Nguyen CT; Gonzales FA; Nichols PW; Yu MC; Jones PA
Prostate; 2000 May; 43(3):233-42. PubMed ID: 10797499
[TBL] [Abstract][Full Text] [Related]
77. Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumors.
Sato K; Schäuble B; Kleihues P; Ohgaki H
Int J Cancer; 1996 May; 66(3):305-8. PubMed ID: 8621248
[TBL] [Abstract][Full Text] [Related]
78. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.
Yarbrough WG; Buckmire RA; Bessho M; Liu ET
J Natl Cancer Inst; 1999 Sep; 91(18):1569-74. PubMed ID: 10491434
[TBL] [Abstract][Full Text] [Related]
79. Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information.
Ruas M; Brookes S; McDonald NQ; Peters G
Oncogene; 1999 Sep; 18(39):5423-34. PubMed ID: 10498896
[TBL] [Abstract][Full Text] [Related]
80. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.
Konecny GE; Winterhoff B; Kolarova T; Qi J; Manivong K; Dering J; Yang G; Chalukya M; Wang HJ; Anderson L; Kalli KR; Finn RS; Ginther C; Jones S; Velculescu VE; Riehle D; Cliby WA; Randolph S; Koehler M; Hartmann LC; Slamon DJ
Clin Cancer Res; 2011 Mar; 17(6):1591-602. PubMed ID: 21278246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
